Annaelle Soubieux
Research Subjects
Research Interests
Annaelle Soubieux has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Eric Barat
Department of Pharmacy, Rouen University Hospital, Rouen, France
2 shared publications - Baptiste Gerard
Department of Rheumatology, Rouen University Hospital, F-76000 Rouen, France
1 shared publication Catherine Chenailler
Department of Pharmacy, Rouen University Hospital, Rouen, France
1 shared publication- Catherine Chenailler
Department of Pharmacy, Rouen University Hospital, F-76000 Rouen, France
1 shared publication - Claire Lattard
Pharmacie des Alpes, F-38300 Domarin, France
1 shared publication Franck Dujardin
Department of Orthopedics, Rouen University Hospital, Rouen, France
1 shared publication
Latest Publications
- Open Access
- 23 July 2024
- Published by MDPI AG in Healthcare
- Vol. 12 (15) , 1463
Impact of the Clinical Pharmacist in Rheumatology Practice: A Systematic Review
This is a systematic literature review on the impact of pharmacists in rheumatology, conducted using the PubMed®, CINAHL®, Cochrane Library®, and Web of science® databases and using the PRISMA 2020 checklist. This review was conducted from 2000 to June 2024. A quality analysis was performed. The selection of articles, as well as all analyses, including quality analyses, were conducted by a pair of pharmacists with experience in rheumatology, and included 24 articles. This study highlights the growth of clinical pharmacy activities in rheumatology and the positive influence of clinical pharmacists on patient care. The implementation of such initiatives has the potential to improve medication adherence, reduce medication-related risks, and optimize associated healthcare costs. All these pharmaceutical interventions aim to make the patient care journey smoother and safer. Additionally, the diversity of available pharmaceutical services caters to the varied needs of rheumatology. Furthermore, outpatient clinical pharmacy is also explored in this field and garners interest from patients. The vast majority of studies demonstrate significant improvement in patient care with promising performance outcomes when pharmacists are involved. This review highlights the diverse range of interventions by clinical pharmacists in rheumatology, which is very promising. However, to better assess the benefits of clinical pharmacists, this activity needs further development and evaluation through controlled and randomized clinical research programs.
- 23 July 2024
- Published by MDPI AG in Healthcare
- Vol. 12 (15) , 1463
Open AccessImpact of the Clinical Pharmacist in Rheumatology Practice: A Systematic Review
This is a systematic literature review on the impact of pharmacists in rheumatology, conducted using the PubMed®, CINAHL®, Cochrane Library®, and Web of science® databases and using the PRISMA 2020 checklist. This review was conducted from 2000 to June 2024. A quality analysis was performed. The selection of articles, as well as all analyses, including quality analyses, were conducted by a pair of pharmacists with experience in rheumatology, and included 24 articles. This study highlights the growth of clinical pharmacy activities in rheumatology and the positive influence of clinical pharmacists on patient care. The implementation of such initiatives has the potential to improve medication adherence, reduce medication-related risks, and optimize associated healthcare costs. All these pharmaceutical interventions aim to make the patient care journey smoother and safer. Additionally, the diversity of available pharmaceutical services caters to the varied needs of rheumatology. Furthermore, outpatient clinical pharmacy is also explored in this field and garners interest from patients. The vast majority of studies demonstrate significant improvement in patient care with promising performance outcomes when pharmacists are involved. This review highlights the diverse range of interventions by clinical pharmacists in rheumatology, which is very promising. However, to better assess the benefits of clinical pharmacists, this activity needs further development and evaluation through controlled and randomized clinical research programs.
- 19 March 2024
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 32 (5) , 399-406
Economic impact of a clinical pharmacist in the orthopaedic sector: a review of the literature
Objectives This review of the literature aimed to evaluate the economic impact of a clinical pharmacist in the orthopaedic sector. Methods The review followed the PRISMA recommendations. A bibliographic search was conducted on 23 June 2023 using PubMed, Cochrane Library and Web of Science. All articles in French or English with economic data on clinical pharmacy activities in orthopaedics were included. Articles not mentioning the term ‘orthopaedics’ and those published prior to 1990 were excluded. Data from the studies were compiled in an Excel table. A bias analysis using the ROBINS-I Cochrane tool was performed. The methodology of the studies was compared and weighted using the CHEERS and STROBE checklists. Results Among 529 articles initially identified, 10 were included in the review. The cost–benefit ratio of a clinical pharmacist in orthopaedics ranged from 0.47:1 to 28:1. The maximum savings reached US$73 410 /year in the American study and €1 42 356 /year in the French study. For three studies, the cost of a clinical pharmacist was not evaluated. Eight studies showed a positive economic impact. The Dutch study showed a balance and the Danish study showed a negative economic impact of €3442/month. Conclusions This literature review has shown an economic benefit of a clinical pharmacist in the orthopaedic sector despite several biases and methodological limitations. The two studies that did not confirm this benefit only evaluated a limited number of expected benefits. Nevertheless, the economic impact of the clinical pharmacist in the orthopaedic sector seems positive and undervalued.
- 19 March 2024
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 32 (5) , 399-406
Economic impact of a clinical pharmacist in the orthopaedic sector: a review of the literature
Objectives This review of the literature aimed to evaluate the economic impact of a clinical pharmacist in the orthopaedic sector. Methods The review followed the PRISMA recommendations. A bibliographic search was conducted on 23 June 2023 using PubMed, Cochrane Library and Web of Science. All articles in French or English with economic data on clinical pharmacy activities in orthopaedics were included. Articles not mentioning the term ‘orthopaedics’ and those published prior to 1990 were excluded. Data from the studies were compiled in an Excel table. A bias analysis using the ROBINS-I Cochrane tool was performed. The methodology of the studies was compared and weighted using the CHEERS and STROBE checklists. Results Among 529 articles initially identified, 10 were included in the review. The cost–benefit ratio of a clinical pharmacist in orthopaedics ranged from 0.47:1 to 28:1. The maximum savings reached US$73 410 /year in the American study and €1 42 356 /year in the French study. For three studies, the cost of a clinical pharmacist was not evaluated. Eight studies showed a positive economic impact. The Dutch study showed a balance and the Danish study showed a negative economic impact of €3442/month. Conclusions This literature review has shown an economic benefit of a clinical pharmacist in the orthopaedic sector despite several biases and methodological limitations. The two studies that did not confirm this benefit only evaluated a limited number of expected benefits. Nevertheless, the economic impact of the clinical pharmacist in the orthopaedic sector seems positive and undervalued.